A detailed history of Paul Damon & Associates, Inc. transactions in Merck & Co., Inc. stock. As of the latest transaction made, Paul Damon & Associates, Inc. holds 2,087 shares of MRK stock, worth $205,235. This represents 0.15% of its overall portfolio holdings.

Number of Shares
2,087
Previous 2,063 1.16%
Holding current value
$205,235
Previous $255 Million 7.18%
% of portfolio
0.15%
Previous 0.17%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$111.15 - $128.97 $2,667 - $3,095
24 Added 1.16%
2,087 $237 Million
Q2 2024

Jul 17, 2024

BUY
$123.8 - $132.96 $6,932 - $7,445
56 Added 2.79%
2,063 $255 Million
Q1 2024

Apr 22, 2024

BUY
$113.24 - $131.95 $12,003 - $13,986
106 Added 5.58%
2,007 $265 Million
Q4 2023

Jan 31, 2024

BUY
$100.18 - $109.02 $190,442 - $207,247
1,901 New
1,901 $207 Million

Others Institutions Holding MRK

About Merck & Co., Inc.


  • Ticker MRK
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,533,280,000
  • Market Cap $249B
  • Description
  • Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, ...
More about MRK
Track This Portfolio

Track Paul Damon & Associates, Inc. Portfolio

Follow Paul Damon & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paul Damon & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Paul Damon & Associates, Inc. with notifications on news.